Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) EBIT (2020 - 2025)

Mirum Pharmaceuticals has reported EBIT over the past 6 years, most recently at -$4.6 million for Q4 2025.

  • Quarterly results put EBIT at -$4.6 million for Q4 2025, up 81.15% from a year ago — trailing twelve months through Dec 2025 was -$22.1 million (up 74.73% YoY), and the annual figure for FY2025 was -$22.1 million, up 74.73%.
  • EBIT for Q4 2025 was -$4.6 million at Mirum Pharmaceuticals, down from $2.6 million in the prior quarter.
  • Over the last five years, EBIT for MIRM hit a ceiling of $2.6 million in Q3 2025 and a floor of -$47.6 million in Q1 2021.
  • Median EBIT over the past 5 years was -$26.8 million (2023), compared with a mean of -$26.2 million.
  • Biggest five-year swings in EBIT: plummeted 116.11% in 2021 and later surged 120.52% in 2025.
  • Mirum Pharmaceuticals' EBIT stood at -$45.6 million in 2021, then grew by 25.04% to -$34.2 million in 2022, then rose by 4.61% to -$32.6 million in 2023, then rose by 25.67% to -$24.2 million in 2024, then skyrocketed by 81.15% to -$4.6 million in 2025.
  • The last three reported values for EBIT were -$4.6 million (Q4 2025), $2.6 million (Q3 2025), and -$5.0 million (Q2 2025) per Business Quant data.